Treatment of chronic idiopathic thrombocytopenic purpura (ITP) with the anti-CD20 monoclonal antibody rituximab was first reported by Perrotta and Abuel in 1998 (1) . Following an initial complete response lasting 5 months, the patient relapsed and was successfully retreated with a second complete response of 5 months duration (2) . Since then, eight patients have received a second remission induction attempt after initial response to this antibody (3) (4) (5) (6) . This is an analysis of the characteristics and response to treatment of these nine patients.
PATIENT SELECTION AND METHODS
A search of the English language literature identified nine patients with ITP who received a second course of rituximab. Excluded were patients with Evan's syndrome (ITP and autoimmune hemolytic anemia), idiopathic thrombocytopenia and idiopathic neutropenia, and all secondary immune thrombocytopenias due to connective tissue diseases, lymphoproliferative disorders, and viral illness. Criteria for response were those of Stasi and colleagues (3) as follows:
• Complete response (CR): An increase of platelets to normal counts; i.e. more than 100 × 10 9 /L.
• Partial response (PR): An increase of platelets to counts between 50 and 100 × 10 9 /L.
• Minor response (MR): An increase of platelets to counts below 50 × 10 9 /L with no need for continued treatment.
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• No response (NR): When there was no increase in platelet count or an increase that did not exceed 50 × 10 9 /L, with a need for continued treatment.
Rituximab was administered intravenously to all patients at a dose of 375 mg/m 2 once weekly, for a total of four infusions for the initial course, as well as re-treatment.
RESULTS
Eight of the nine patients were female with a mean and median age, respectively, of 52 and 53 years (range, 27-74) ( Table 1) . Duration of disease before initial treatment with rituximab was a mean of 4 years and median of 3 years (range, 10 months to 10 years). Of the nine patients, the two who failed the second course had not undergone splenectomy. Both had achieved a CR to the initial course and a maximum platelet count response in 4 weeks.
Duration of response to the first course of rituximab for all patients was a mean of 19.7 weeks and median of 29 weeks (range, 3 to 32 weeks). Duration of response to the first and second course, available in four patients, was 5, 5 months; 1.25, 8 months; 6, 7+ months; and 8, 18+ months, respectively.
Prior response to therapies before rituximab was recorded in four patients. All four had responded to intravenous immunoglobulin (IVIg).
DISCUSSION
The data suggest that females are predominantly selected for or suitable for both initial treatment and re-treatment (female/male ratio of 8) because the largest prospective series of rituximab-treated adults with ITP by Cooper and colleagues (7) has a female/male ratio of 2.8 but gender did not affect response in that study. A total of 95 evaluable patients have been treated with rituximab in reports published between December 1998 and June 2003 (1) (2) (3) (4) (5) (6) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The female/male ratio was 2, but almost three times as many females as males responded to rituximab. Adult ITP is more common in women, but the female/male ratio is only 1.7 (17) .
Cooper and colleagues (7) observed three distinct patterns of platelet increase in 18 complete responders to their first course of rituximab:
• Seven of their patients (39%) had an immediate response, achieving normal counts by week 4.
• Five patients (28%) responded between weeks 7 and 11.
• Six patients (33%) achieved a normal platelet count between weeks 13 and 31.
These distinct time courses of platelet response suggested to the authors that there might be more than one mechanism whereby rituximab increases the platelet count in patients with ITP. Eight of nine patients in this current review who were re-treated had an immediate response. There was only one who responded at 8 weeks. That patient had the longest duration of complete remission of 18 months upon re-treatment. The patients of Cooper and colleagues (7) who had a longer duration of ITP (>15 years) were less likely to respond. The longest duration of disease before treatment with rituximab in this review was 10 years. They also observed that duration of response to initial treatment with rituximab was strongly correlated with the magnitude of response. Sixteen of 18 (89%) of their patients who had achieved a CR still had normal platelet counts at a median of 72 weeks (range, 24-165 weeks) from initial infusion. In this review, the second course resulted in a CR in all six patients where this was recorded despite the initial responses of two PRs and one MR in three of the six. Response to re-treatment was at least as durable and more so than the first course ( Table 1) .
There is a suggestion that splenectomy improves the chances of a second response to rituximab because two of the three patients who had not undergone splenectomy did not respond to a second course, although Cooper and colleagues (7) observed that splenectomy did not influence either the likelihood of initial response or characteristics of that response. Prior response to IVIg may predict both initial and subsequent response. The influence of prior splenectomy, response to IVIg, and distinct patterns of time course until platelet response suggest there might be different mechanisms of response to rituximab.
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